Click here to view online. Add this email to your safelist.

AstraZeneca logo

AstraZeneca’s triple-combination therapy approved in China for patients with COPD

23 December 2019

AstraZeneca today announced that budesonide/glycopyrronium/formoterol fumarate has been approved in China for the maintenance treatment of chronic obstructive pulmonary disease (COPD).

Read more  Read more

RSS Feed  RSS Feed Twitter  Follow us on Twitter LinkedIn  Follow us on LinkedIn
Legal notice and Terms of Use Privacy policy Cookie policy Site map © AstraZeneca 2019

For more information please visit astrazeneca.com.

If you would like to unsubscribe please click here.